Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baptiste Pignon

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Schizophrenia Bulletin Open|December 13, 2021
Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) StudyMarion Leboyer, Ophélia Godin, Emilie Terro, et al.
Brain, Behavior, & Immunity - Health|April 26, 2022
Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohortMarianne Foiselle, Susana Barbosa, Ophélia Godin, et al.
Journal of Psychosomatic Research|June 25, 2025
Clinical and inflammatory markers associated with metabolic dysfunction-associated fatty liver disease in a cohort of individuals with chronic schizophrenia (FACE-SZ)Rudy Tokarski, Susana Barbosa, Baptiste Pignon, et al.
Psychiatry Research|June 3, 2025
Pro-inflammatory processes and metabolic syndrome: combined risk of resistance to treatment in patients with schizophrenia from the FACE-SZ cohortKaori Saitoh, Mohamed Lajnef, Wahid Boukouaci, et al.
Brain, Behavior, & Immunity - Health|October 6, 2025
Inflammation, childhood trauma, and symptom dimensions in schizophrenia: a path-analysis studyFrancisca Silva, Andrei Szöke, Mohamed Lajnef, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 15, 2025
Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiquesBenjamin W Bond, Bea Duric, Edoardo Spinazzola, et al.
Schizophrenia Research|July 30, 2024
Corrigendum to "Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study" [Schizophr. Res. volume 225 (May 2023) 173-181]Edward Millgate, Sophie E Smart, Antonio F Pardiñas, et al.
Schizophrenia Research|March 31, 2023
Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort studyEdward Millgate, Sophie E Smart, Antonio F Pardiñas, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 1, 2025
Prediction of relapse in a French cohort of outpatients with schizophrenia (FACE-SZ): Prediction, not associationSusana Barbosa, Ryad Tamouza, Marion Leboyer, et al.
Psychological Medicine|February 5, 2025
Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factorsLaura Ferraro, Marta Di Forti, Daniele La Barbera, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Schizophrenia Bulletin Open|December 13, 2021
Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) StudyMarion Leboyer, Ophélia Godin, Emilie Terro, et al.
Brain, Behavior, & Immunity - Health|April 26, 2022
Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohortMarianne Foiselle, Susana Barbosa, Ophélia Godin, et al.
Journal of Psychosomatic Research|June 25, 2025
Clinical and inflammatory markers associated with metabolic dysfunction-associated fatty liver disease in a cohort of individuals with chronic schizophrenia (FACE-SZ)Rudy Tokarski, Susana Barbosa, Baptiste Pignon, et al.
Psychiatry Research|June 3, 2025
Pro-inflammatory processes and metabolic syndrome: combined risk of resistance to treatment in patients with schizophrenia from the FACE-SZ cohortKaori Saitoh, Mohamed Lajnef, Wahid Boukouaci, et al.
Brain, Behavior, & Immunity - Health|October 6, 2025
Inflammation, childhood trauma, and symptom dimensions in schizophrenia: a path-analysis studyFrancisca Silva, Andrei Szöke, Mohamed Lajnef, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 15, 2025
Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiquesBenjamin W Bond, Bea Duric, Edoardo Spinazzola, et al.
Schizophrenia Research|July 30, 2024
Corrigendum to "Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study" [Schizophr. Res. volume 225 (May 2023) 173-181]Edward Millgate, Sophie E Smart, Antonio F Pardiñas, et al.
Schizophrenia Research|March 31, 2023
Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort studyEdward Millgate, Sophie E Smart, Antonio F Pardiñas, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 1, 2025
Prediction of relapse in a French cohort of outpatients with schizophrenia (FACE-SZ): Prediction, not associationSusana Barbosa, Ryad Tamouza, Marion Leboyer, et al.
Psychological Medicine|February 5, 2025
Cognitive presentation at psychosis onset through premorbid deterioration and exposure to environmental risk factorsLaura Ferraro, Marta Di Forti, Daniele La Barbera, et al.
Pageof 11